- Home
- ZIP vs INBX Comparison
ZIP vs INBX Comparison
Compare ZIP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | INBX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.3M | 430.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZIP | INBX |
|---|---|---|
| Price | $3.22 | $73.16 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $4.88 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 247.1K |
| Earning Date | 02-24-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,299,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.22 | $10.81 |
| 52 Week High | $8.23 | $94.57 |
Technical Indicators
Market Signals| Indicator | ZIP | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 21.42 | 38.55 |
| Support Level | $4.09 | $72.90 |
| Resistance Level | $4.00 | $80.00 |
| Average True Range (ATR) | 0.20 | 5.35 |
| MACD | -0.10 | -1.25 |
| Stochastic Oscillator | 5.41 | 9.13 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.